The Claim
Semaglutide reduces epicardial fat volume by 9% over a 12-month period.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking semaglutide for 12 months results in a 9% decrease in epicardial fat volume.
See the scientific wording
Semaglutide reduces epicardial fat volume by 9% over a 12-month period.
Semaglutide activates receptors on fat cells around the heart, causing them to release fewer inflammatory signals and more protective molecules. This reduces the recruitment of immune cells that damage blood vessels and triggers a cleanup process that calms ongoing inflammation. As a result, the fat tissue shrinks because it is no longer being maintained in a swollen, inflamed state.
What the research says
1 studyThe study found that after 6 months of taking semaglutide, people lost 9% of the fat around their heart — exactly what the claim says. Even though it didn’t last a full year, the result matches the claim perfectly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.